Hydra Biosciences to have Phase 1 TRPA1 data soon
Closely-held Hydra Biosciences expects to complete Phase 1 trials of its HX-100 inhibitor of the Transient Receptor Potential (TRPA1) ion channel as a treatment for painful diabetic neuropathy and...
View ArticleCellectar gets NCI grant for PDC platform
Cellectar Biosciences (NASDAQ:CLRB) has received initial notice of award for a Phase I-II Fast-Track Small Business Innovation Research (SBIR) grant. The SBIR grant provides up to $2.3-million over 2...
View Article
More Pages to Explore .....